

# Index

## A

Activation mechanism, 45, 46, 50  
Ahmed, J., 191  
Alignment free method, 209, 211, 214, 219  
All-atom simulations, 80, 81, 89, 91  
Allen, T.W., 116  
Andrews, S.P., 135  
 $\beta$ -Arrestin, 38, 170  
Audet, M., 8

## B

Baldwin, J., 6, 8  
Ballesteros, J.A., 16, 45  
Bellis, L.J., 189  
Benjamin, T., 135  
Berman, H.M., 198  
Beuming, T., 195  
Bhattacharya, S., 37  
Biased agonism, 107, 170  
Biased simulations, 115, 116  
Biogenic amines, 17, 19–22, 40–41, 50  
Bioinformatics, 205–220  
Bitter taste receptors, 191, 192  
Blättermann, S., 135, 143  
Bolton, E., 189  
Bouvier, M., 8, 45

## C

Carlsson, J., 135, 146  
Cavasotto, C.N., 198  
Cheng, F., 189  
Chen, X., 189  
Cherezov, V., 17  
Chien, E.Y., 17  
Choe, H.W., 17  
Cholesterol-GPCR binding, 69  
Class, 4, 5, 19, 22, 24, 25, 27, 38, 40, 41, 59, 76, 96, 106, 131, 134, 141, 146, 147, 150, 172, 178, 186, 190, 199, 206–209, 213, 214, 216, 217, 219  
Coarse-graining, 46, 47, 62, 63, 75–91, 96, 112–113  
Conformation, 6, 7, 9, 16–25, 27, 29, 38, 39, 41–48, 51, 57, 59, 76, 86, 96, 99, 103–111, 133, 143, 145, 165, 170, 172, 194

Conformational states, 38, 39, 46, 47, 64, 110  
Congreve, M., 135  
Continuum elastic theory, 65  
Continuum-Molecular Dynamics (CTMD), 61–63, 65–69, 193, 194  
Cordomí, A., 15  
Costanzi, S., 3, 5, 7, 136, 142  
Craστο, C.J., 191  
Croft, D., 195  
Crystal structures, 6, 8–10, 15–29, 39, 40, 42–48, 50, 63, 78, 80, 81, 89, 96–99, 101, 103, 104, 107–110, 113, 117, 120, 130, 131, 134, 135, 140–151  
CTMD. *See* Continuum-Molecular Dynamics (CTMD)  
Curation, 190  
Curve fitting, 163

## D

Database cross referencing, 186  
Databases, 10, 106, 131–136, 141–146, 185–201, 209–211, 214–216  
de Esch, I.J.P., 129  
de Graaf, C., 129, 135, 136, 146, 149  
DHA. *See*  $\omega$ -3 Docosahexaenoic acid (DHA)  
Dimerization, 41, 56, 89, 107, 113–119, 168, 194  
Dimers, 25, 27, 76, 113, 114, 116, 119, 168–173  
3D models, 190, 197, 199  
Docking, 7, 9, 10, 97, 98, 103, 106, 132–134, 136, 140–143, 145, 146, 148, 149, 192, 198, 199  
 $\omega$ -3 Docosahexaenoic acid (DHA), 57, 58, 60, 69, 77, 78, 83–86, 90  
Dopamine receptor, 40, 42, 144  
Dror, R.O., 46, 97, 102  
Drug design, 43–47, 111, 148, 197, 206, 219, 220  
Duan, Y., 99  
Dunkel, M., 191

## E

Elefsinioti, A.L., 195  
Empirical modeling, 161–167, 173–176  
Enhanced methods, 46, 95–120  
Evolutionary algorithm (EA), 178

**F**

Family, 4, 6, 7, 9, 15, 16, 20, 22, 24, 28, 40, 41, 56, 76, 130, 131, 177, 188–192, 195, 196, 198, 199, 206, 207, 209–211, 213–220  
 Filizola, M., 95, 219  
 Frauenfelder, H., 96  
 Fredriksson, R., 209  
 Free-energy calculations, 215  
 Friesner, R.A., 9  
 Function, 3, 10, 24, 50, 57, 59, 61, 67, 69, 70, 75–78, 81–82, 95, 101, 105, 109, 115–117, 129, 136, 140, 159–178, 192, 196, 206, 209, 214, 215, 219, 220  
 Functional microdomains in GPCRs, 57  
 Functional selectivity, 107, 148–151, 170–173, 176

**G**

Galizia, C.G., 191  
 Gatica, E.A., 198  
 Gil, D., 159  
 Giraldo, J., 159  
 Gonzalez, A., 15, 102  
 Goto, S., 195  
 G-protein, 4, 8, 15, 20, 25, 27, 28, 38, 39, 45, 47, 50, 149, 151, 186, 194–196, 206, 207, 209, 214, 217–219  
 G-protein coupled receptors (GPCR)  
 activation, 21, 44, 46, 173, 219  
 discrimination, 210, 211, 214–216  
 dynamics, 37–51  
 function, 57, 58, 70, 165, 206, 209–220  
 structure, 4, 5, 7, 9–11, 39–47, 50, 58, 96, 129–151, 197, 200, 201, 208  
 Granier, S., 17  
 Grossfield, A., 75

**H**

Haga, K., 17  
 Hanson, M.A., 17  
 Hargrave, P., 5  
 Harmar, A.J., 189  
 Hecker, N., 189  
 Hierarchical GPCR classification, 211, 216–218  
 Hill coefficient, 161, 163–165, 168  
 Homology, 3–11, 16, 28, 63, 97–98, 103, 105, 107, 111, 113, 117, 130, 133, 136, 137, 140–147, 149, 151, 189–193, 197–199  
 Homology modeling, 3–11, 16, 28, 97, 98, 107, 113, 128, 136, 151  
 Hopf, T.A., 198  
 Horn, F., 189  
 Horn, J.N., 75  
 Huang, J., 17  
 Hydrophobic mismatch, 62–65, 69, 76, 77, 79, 112, 113, 194

**I**

In silico methods, 143  
 Interface, 25, 27, 41, 48, 60, 62–64, 66–69, 75, 76, 78, 87, 89, 90, 113–120, 131, 193, 219

Intrinsic efficacy, 166, 168, 173, 175  
 Inverse agonism, 167  
 Isberg, V., 105, 106  
 Istyastono, E.P., 135

**J**

Jaakola, V.P., 17  
 Jacobson, K.A., 5, 7  
 Johnner, N., 55  
 Johnston, J.M., 95

**K**

Kanehisa, M., 195  
 Kao, T.-C., 75  
 Karchin, R., 209  
 Katritch, V., 10, 135  
 Keshava Prasad, T.S., 193  
 Khelashvili, G., 55, 193  
 Kim, J., 135, 143, 147, 215  
 Kimura, S.R., 97, 98  
 Kleinau, G., 191  
 Kobilka, B.K., 3, 8, 47  
 Kolb, P., 135, 141, 145  
 Kooistra, A.J., 129  
 Kouyama, T., 17  
 Kowalsman, N., 185  
 Kruse, A.C., 17

**L**

Langmead, C.J., 135, 146  
 Lapnish, M., 211, 216  
 Larsen, A.B., 37  
 Launay, G., 198  
 Lefkowitz, R.J., 3, 4, 6, 8  
 Leurs, R., 129  
 Ligand binding, 7, 23, 25, 28, 38, 39, 41, 42, 45, 47, 48, 50, 51, 57, 63–65, 96–104, 107, 122, 142, 148, 151, 153, 178, 187, 189, 199, 207  
 Ligand recognition, 9, 56, 67–104  
 Ligand sets, 106, 189, 198  
 Li, J., 195  
 Lin, X., 135, 145, 147  
 Lipid–protein interactions, 58, 69, 75–76, 79, 80  
 Liu, T., 189  
 Liu, W., 17  
 Liu, X., 191  
 Lomize, M.A., 198

**M**

Machine learning method, 209, 211–214, 216, 219  
 Manglik, A., 17  
 Mathematical modeling, 160, 177  
 Matsoukas, M., 15  
 Mechanistic modeling, 159–178  
 Membrane deformation energy, 65, 69  
 Membrane mismatch, 60–62

- Metadynamics, 47, 103–104, 107–111, 113, 117, 118  
Models,  
Molecular dynamics (MD) simulations, 45, 46,  
49, 50, 58–60, 62, 63, 65–69, 78, 80, 81,  
96–99, 101–103, 105, 106, 108, 111, 113,  
116, 151  
Molecular mechanisms, 8, 39, 95–120, 151  
Mondal, S., 55, 64, 193  
Motif based search, 216  
Murakami, M., 17  
Mysinger, M.M., 135
- N**  
Nemoto, W., 193  
Niv, M.Y., 185
- O**  
Okuno, Y., 189  
Olender, T., 191  
Oligomerization, 25–27, 62–64, 70, 79, 94, 96, 111–120,  
168, 187, 189, 190, 192–194, 209, 219  
Operational model, 173–176  
Ovchinnikov, Y., 5
- P**  
Palczewski, K., 6, 17  
Parameter optimization, 177  
Pardo, L., 15  
Park, J.H., 17  
Parrinello, M., 81  
Partners, 4, 21, 86, 111, 185–201, 209  
Periole, X., 113, 117–119  
PPI. *See* Protein–protein interactions (PPI)  
PPI network classification, 210, 211  
Predictions, 10, 41, 47, 65, 79, 113, 135, 145, 148, 193,  
194, 196, 199–201, 209–220  
Protein function, 75, 76, 209  
Protein–protein interactions (PPI), 58, 69, 70, 75–76, 79,  
210, 211, 218–219
- R**  
Rahman, A., 81  
Rasmussen, S.G., 17  
Receptor constitutive activity, 165, 173–176  
Receptor dimer, 114, 116, 168, 192  
Receptor oligomerization, 25–27, 62  
Renault, N., 135, 145  
Repository, 194, 198, 201  
Residual exposure, 62–70  
Residual mismatch, 56  
Rhodopsin, 4–10, 17, 21, 22, 24, 25, 27, 44, 45, 48,  
57, 59–64, 67–69, 75–90, 97–101, 104–107,  
109–113, 117–120, 130, 134, 193, 194, 206, 208,  
209, 217  
Roche, D., 159  
Rodriguez, D., 198  
Rognan, D., 136, 149  
Rosenbaum, D.M., 17, 111  
Roth, B.L., 189  
Roux, B., 115, 116
- S**  
Safran, M., 191  
Satagopam, V.P., 195  
Saunders, B., 195  
Scheerer, P., 17  
Selvam, B., 102  
Sequence similarity search, 4, 8, 10, 16, 207, 209,  
210, 216  
Serotonin receptor, 57, 59, 104, 106, 107, 109,  
186–188, 197  
Serrano-Vega, M.J., 49  
Servers, 185–201, 216, 220  
Sgourakis, N.G., 195  
Shimamura, T., 17  
Shoichet, B.K., 10  
Signal transduction, 15, 28, 38, 50, 56, 77, 111, 173, 175,  
186, 194, 195, 206, 218, 220  
Simpson, L.M., 104–107  
Sirci, F., 135, 143  
Standfuss, J., 17  
Stark, C., 193  
Statistical model method, 209, 211  
Steyaert, J., 47  
Strader, D., 4, 8  
Structure and remodeling of lipid membranes, 60–62  
Structure–function relations in GPCRs, 58–65  
Subfamily, 18, 22, 23, 41, 207, 209, 214, 216–219  
Sum, C.S., 136  
Surgand, J.S., 136  
Suwa, M., 205
- T**  
Taddese, B., 107  
Thermostable mutants, 39, 47–49, 51  
Tikhonova, I.G., 136  
TMH. *See* Transmembrane helix (TMH)  
Topiol, S., 141  
Torrìe, G.M., 114  
Tosh, D.K., 148  
Transmembrane helix (TMH), 16–21, 44, 50,  
81, 117  
Transmembrane proteins, 50, 62, 65, 66, 77, 199  
Two-state model, 165–168
- U**  
Umbrella sampling, 113, 115–119
- V**  
Vaidehi, N., 37  
Valleau, J.P., 114

Van Durme, J., 191  
Virtual screening, 10, 97, 104, 106, 107, 131–150, 197,  
198

**W**

Wacker, D., 17  
Wang, C., 17  
Wang, K., 3  
Wang, T., 99, 101, 102  
Wang, Y., 189  
Warne, T., 17  
Weinstein, H., 16, 55  
Weinstein, J., 45  
Wenstein, H., 219  
White, J.F., 17  
Wiener, A., 191

Worth, C.L., 198  
Wu, B., 17  
Wu, H., 17

**X**

X-ray crystallography, 6, 7, 9, 10, 106,  
120, 197  
Xu, F., 17

**Z**

Zachmann, J., 15  
Zhang, C., 17  
Zhang, J., 198  
Zhang, Y., 198  
Zhu, F., 189